Quinazoline compound
PK139921AUndetermined Publication Date: 2009-01-17ASTRAZENECA UK LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- PK199700826
- Authority / Receiving Office
- PK · PK
- Patent Type
- Applications
- Current Assignee / Owner
- Publication Date
- 2009-01-17
Abstract
The invention concerns quinazoline compound of the formula 1 wherein n is 1, 2 or 3 and each R2 is independently halogeno, trifluoro methyl or (l-4C)alkyl; R3 is (1-4C)alkoxy; and R 1 is di-[(l-4C)alkyl]amino-(2-4C)alkoxy, pyrrolidin-l-yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1 -yl -(2-4C)alkoxy, 4-(l -4C)alky Ipiperazin-1-yl-(2-4C)alkoxy, imidazol-1 -yl-(2-4C)alkoxy, di-[(l-4C)alkoxy-(2-4C)alkyl]amino-(2-4C)alkoxy, thiamorpholino-(2-4C)alkoxy, 1 -oxothiamorpholino-(2-4C)alkoxy or 1,1 -dioxothiamorpholino-(2-4C)alkoxy, and wherein any of the above-mentioned R1 subsiituents comprising a CH2 (methylene) group which is not attached to a N or O atom optionally bears on said CH2 group a hydroxyl substituent; pharmaceutical composition containing it, and the use of the receptor tyrosine kinase inhibitory properties of the compound in the treatment of proliferative disease such as cancer.
Need to check novelty before this filing date? Find Prior Art
